Skip to main content
SpringerLink
Log in

Emergencies of Calcium Homeostasis

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Van Cromphaut SJ, Dewerchin M, Hoenderop JGJ, Stockmans I, Van Herck E, Kato S, Bindels RJM, Collen D, Carmeliet P, Bouillon R, Carmeliet G. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. PNAS 2001;98:13324–13329.

    Google Scholar 

  2. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345–357.

    Google Scholar 

  3. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AHG, Rubens RD, for the International Bone and Cancer Study Group. Current use of bisphosphonates in oncology. J Clin Oncol 1998;16:3890–3899.

    Google Scholar 

  4. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994;73:2223–2230.

    Google Scholar 

  5. de Wit S, Cleton FJ. Hypercalcemia in patients with breast cancer: A survival study. J Cancer Res Clin Oncol 1994;120:610–614.

    Google Scholar 

  6. Body JJ, Delmas PD. Urinary pyridinium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992;74:471–475.

    Google Scholar 

  7. Dumon JC, Wantier H, Mathieu F, Mantia M, Body JJ. Technical and clinical validation of a newimmunoradiometric assay for human osteocalcin. Eur J Endocrinol 1996;135:231–237.

    Google Scholar 

  8. Nagai Y, Yamato H, Akaogi K, Hirose K, Ueyama Y, Ikeda K, Matsumoto T, Fujita T, Ogata E. Role of interleukin-6 in uncoupling of bone in vivo in a human squamous carcinoma coproducing parathyroid hormone-related peptide and interleukin-6. J Bone Miner Res 1998;13:664–672.

    Google Scholar 

  9. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, Hata K, Hane M, Tamura Y, Tanaka Y, Kitaoka M, Obara T, Ogata E, Matsumoto T. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancyassociated hypercalcemia. J Clin Endocrinol Metab 1996;81:607–611.

    Google Scholar 

  10. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ. Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991;73:1309–1315.

    Google Scholar 

  11. Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. Arch Intern Med 1991;151:471–476.

    Google Scholar 

  12. Kanis JA, McCloskey EV. Bisphosphonates in the treatment of multiple myeloma. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. New York &; Basel: Marcel Dekker Inc, 2000:457–481.

    Google Scholar 

  13. Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 1984;53:359–368.

    Google Scholar 

  14. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichinitser MR, Rizzoli R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ. Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295–300.

    Google Scholar 

  15. Body JJ. Current and future directions in medical therapy: Hypercalcemia. Cancer 2000;88:3054–3058.

    Google Scholar 

  16. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone and Mineral 1991;15:257–266.

    Google Scholar 

  17. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993;67:560–563.

  18. Shah S, Hardy J, Rees E, Ling J, Gwilliam B, Davis C, Broadley K, A'Hern R. Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? Br J Cancer 2002;86:1235–1237.

    Google Scholar 

  19. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289–1293.

    Google Scholar 

  20. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997;8:915–916.

    Google Scholar 

  21. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30, 60, 90 mg doses. Am J Med 1993;95:297–304.

    Google Scholar 

  22. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 1994;5:359–363.

    Google Scholar 

  23. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993;341:1611–1613.

    Google Scholar 

  24. Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related protein. Br J Cancer 1994;70:169–172.

    Google Scholar 

  25. Rizzoli R, Thiebaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Ruckert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thurlimann B, Clemens MR, Eghbali H, Body JJ. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999;84:3545–3550.

    Google Scholar 

  26. Body JJ, Louviaux I, Dumon JC. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Supportive Care in Cancer 2000;8:398–404.

    Google Scholar 

  27. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745–751.

    Google Scholar 

  28. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268–276.

    Google Scholar 

  29. Pecherstorfer M, Steinhauer E, Pawsey SD. Ibandronic acid is more effective than pamidronic in lowering serum calcium inpatients with severe hypercalcemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calcium levels. Results of a randomised open label, comparative study. Proceedings of ASCO 2001;20:385A.

    Google Scholar 

  30. Oleffe V, Dumon JC, Body JJ. Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: Effects of bisphosphonate therapy and surgery. J Surg Oncol 1996;63:125–129.

    Google Scholar 

  31. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557–1561.

    Google Scholar 

  32. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HG, Yunus F, Bell R, Body JJ, Quebe-Fehling E, Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–567.

    Google Scholar 

  33. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999;141:195–210.

    Google Scholar 

  34. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Sarosi I, Lacey DL, Dunstan CR. Comparison of osteoprotegerin and pamidronate in a murine model of humoral hypercalcemia of malignancy. J Bone Miner Res 1999;14 (Suppl 1):S163.

    Google Scholar 

  35. Rosen LS, Gordon D, Antonio BS, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.

    Google Scholar 

  36. Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: Effect on clinical status. Clin Endocrinol 1990;32:293–300.

    Google Scholar 

  37. Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 1991;110:480–486.

    Google Scholar 

  38. Marcus R. Diagnosis and treatment of hyperparathyroidism. Rev Endocr Metab Disord 2000;1:247–252.

    Google Scholar 

  39. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001;16:113–119.

    Google Scholar 

  40. Grey A. Primary hyperparathyroidism: Medical management. Clin Rev in Bone and Mineral Metabolism 2002;1:35–42.

    Google Scholar 

  41. Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol 1995;43:531–536.

    Google Scholar 

  42. Rizzoli R, Stoermann C, Ammann P, Bonjour JP. Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronate therapy. Bone 1994;15:193–198.

    Google Scholar 

  43. Sandler LM, Winearls CG, Fraher LJ, Clemens TL, Smith R, O'Riordan JLH. Studies of the hypercalcemia of sarcoidosis: Effects of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Quaterly Journal of Medicine, new series LIII 1984;210:165–180.

    Google Scholar 

  44. Chesney RW, Hamstra AJ, DeLuca HF, Horowitz S, Gilbert EF, Hong R, Borcherding W. Elevated serum 1,25-dihydroxyvitamin D concentrations in the hypercalcemia of sarcoidosis: Correction by glucocorticoid therapy. J Pediatr 1981;98:919–922.

    Google Scholar 

  45. Kozeny GA, Barbato AL, Bansal VK, Vertuno LL, Hano JE. Hypercalcemia associated with silicone-induced granulomas. N Engl J Med 1984;311:1103–1105.

    Google Scholar 

  46. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363–375.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Institut J. Bordet, Université Libre de Bruxelles, Brussels, Belgium

    Jean-Jacques Body

  2. Legendo, Onderwijs en Navorsing, Katholieke Universiteit Leuven, Belgium

    Roger Bouillon

Authors
  1. Jean-Jacques Body
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger Bouillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Body, JJ., Bouillon, R. Emergencies of Calcium Homeostasis. Rev Endocr Metab Disord 4, 167–175 (2003). https://doi.org/10.1023/A:1022994104070

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022994104070

Search

Navigation